Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.86M P/E - EPS this Y 53.70% Ern Qtrly Grth -
Income -7.37M Forward P/E -2.23 EPS next Y 47.50% 50D Avg Chg -1.00%
Sales 667k PEG - EPS past 5Y - 200D Avg Chg -32.00%
Dividend N/A Price/Book 1.38 EPS next 5Y - 52W High Chg -71.00%
Recommedations 2.00 Quick Ratio 2.38 Shares Outstanding 6.10M 52W Low Chg 91.00%
Insider Own - ROA -57.46% Shares Float 1.67B Beta 0.65
Inst Own 9.80% ROE -157.62% Shares Shorted/Prior 202.21K/175.73K Price 2.90
Gross Margin 100.00% Profit Margin - Avg. Volume 22,788 Target Price 13.33
Oper. Margin -1,295.57% Earnings Date Nov 28 Volume 9,830 Change -4.29%
About Can-Fite Biopharma Ltd Sponsore

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Can-Fite Biopharma Ltd Sponsore News
11/11/24 Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11/05/24 Can-Fite BioPharma Secures Australian Patent for Obesity Drug
11/04/24 Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
10/18/24 Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
10/09/24 FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
10/07/24 Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
09/24/24 Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
09/16/24 Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
08/30/24 Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
08/29/24 Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
08/09/24 OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
08/08/24 Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
07/29/24 Can-Fite Provides Namodenoson Patent Update
07/17/24 Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
07/11/24 Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
07/01/24 Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
06/28/24 Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
06/24/24 Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
06/10/24 Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
06/05/24 Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
CANF Chatroom

User Image Erikg19 Posted - 1 day ago

$CANF wonder why someone gave me some $1.96's..... hahaha - Ok.... thanks, I guess. #biotech

User Image rickahuna Posted - 6 days ago

$CANF I love the fact that the pipeline is small molecule drugs, which means they are cheap to manufacture, and that they seem to be effective in multiple diseases. Targeting inflammation already allows expansion of the many diseases related to inflammation. Vetbiolix, Can-Fite’s veterinary commercialization partner, covered all costs of the completed study. Vetbiolix already exercised its option to enter into a full in-license agreement with Can-Fite and is obligated to pay Can-Fite an upfront payment, milestone payments and royalties on sales upon regulatory approval, summing up to projected income of $325M to Can-Fite over the next 10 years. Nov 11, 2024 7:00am EST Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Nov 04, 2024 7:08am EST anti-Obesity Drug Namodenoson Received Patent Allowance in Australia Oct 09, 2024 7:00am EDT FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

User Image Thestocktraderhubzee Posted - 1 week ago

WATCHLIST NOV 12 2024 $CANF HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target $NVAX HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target $ZETA Needham Maintains Buy on Zeta Global Holdings, Raises Price Target to $43 $APP Loop Capital Maintains Buy on AppLovin, Raises Price Target to $385 $NXTC HC Wainwright & Co. Maintains Buy on NextCure, Lowers Price Target to $4

User Image Erikg19 Posted - 1 week ago

$CANF That's it, I'm cleared to purchase a sizable amount again this week. Seems to have support in low $2's so I'll be buying the rest of the week as I see more volume. I see this potential with the next release of data/news/ or a deal/partnership to begin its rise to $15+ #biotech #obesity is #america

User Image OpenOutcrier Posted - 1 week ago

$CANF (+5.2% pre) Can-Fite BioPharma (CANF) anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - SI https://ooc.bz/l/47599

User Image Danypoopoo Posted - 1 week ago

$CANF https://ir.canfite.com/news-events/press-releases/detail/1071/can-fite-achieves-milestone-with-first-patient-dosing-in

User Image Erikg19 Posted - 2 weeks ago

$CANF We'll need more than 3 of us to get this moving. With the potential I'm not sure why we're still stuck in low $2's. Once we're "seen" and there's a bit more data, we'll be at $5 in a day. We'll see. Still patient w/ this one. GL $biotech

User Image JClem_Stocks Posted - 2 weeks ago

$FREY make sure to check out $CANF…. Tiny market cap of $15 million and they have partnership with $300 million revenue over the next 10 Years for only one of their products…. Very low volume…. Get in while you can

User Image JClem_Stocks Posted - 2 weeks ago

$CANF this one is going to explode eventually, patience (volume is low). Major catalysts of revenue over 20x their entire market cap over the next 10 years. Patience, because this one could potentially run to $10-$20 per share.

User Image briefingcom Posted - 2 weeks ago

$CANF: Can-Fite BioPharma announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241104071113CANF&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image bsome191 Posted - 2 weeks ago

$CANF

User Image Danypoopoo Posted - 2 weeks ago

$CANF https://finance.yahoo.com/news/fite-anti-obesity-drug-namodenoson-120800357.html

User Image Erikg19 Posted - 2 weeks ago

$CANF yep.... so light it's easy for them to move it anyway they want. Adding again on day 9 of this BS down trend. Will pop fast in time. GL

User Image JClem_Stocks Posted - 2 weeks ago

$CANF adding the dips

User Image Erikg19 Posted - 10/30/24

$CANF Off the low... reversal coming.....again? Seems right but you never know. Last bit of buying for me for now. GL #biotech

User Image Erikg19 Posted - 10/29/24

$CANF 6 day "pause". Ready to continue uptrend. Will add again on any further drop unless news isn't favorable. If we continue back up & reach $3 again I think we can keep it and continue the up-trend with shorter pull backs. Still, need more volume and maybe some more data/news to propel this forward. #biotech

User Image Danypoopoo Posted - 1 month ago

$CANF

User Image Crosado Posted - 1 month ago

$CANF wild this news and nothing happening here 🫣…325million rev for the next 10years, market cap sits at 20mil?!

User Image Dat_boi Posted - 1 month ago

$CANF 1b potential market cap

User Image Erikg19 Posted - 1 month ago

$CANF Moving.... I like that there's a bit of a slow start. When more people realize the potential we'll see the volume/price really start to go. #biotech

User Image Dat_boi Posted - 1 month ago

$CANF 1b market cap

User Image briefingcom Posted - 1 month ago

$CANF: Can-Fite BioPharma announces that its veterinary partner Vetbiolix reported positive final results from the osteoarthritis multicenter clinical study in dogs treated with Piclidenoson https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241018090750CANF&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image CABTC Posted - 1 month ago

$CANF - News gone under the radar, once it gets out this will go crazy $SUNE - HUGE HUGE WIN $DRUG - MENTAL

User Image CABTC Posted - 1 month ago

$JDZG - Reversal incoming 🔄 $CANF - Deal flying under the radar, loading levels $2.75

User Image CABTC Posted - 1 month ago

$CANF - Deal flown completely under the radar. Loading before it gets out $SUNE - WHAT A MOVE. TRIPLE TOP THERE. Could explode more $DRUG - This thing just refuses to die. HUGE win for some!

User Image CABTC Posted - 1 month ago

$CANF $SUNE sold for profit at 11.5 now going into $CANF

User Image Dat_boi Posted - 1 month ago

$CANF potential 3b market cap

User Image Dat_boi Posted - 1 month ago

$CANF https://www.stocktitan.net/news/CANF/significant-positive-results-from-osteoarthritis-clinical-study-in-ugb2xk69at2o.html

User Image CABTC Posted - 1 month ago

$CANF and $CDT hot

User Image CABTC Posted - 1 month ago

$CANF - BIG DEAL FLYING UNDER THE RADAR. BUYING OPPORTUNITY HERE

Analyst Ratings
EF Hutton Buy Jul 17, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Oct 24, 23
HC Wainwright & Co. Buy Jun 2, 23
HC Wainwright & Co. Buy Mar 13, 23